吉西他滨与顺铂二线治疗晚期三阴乳腺癌的效果观察

刘树松，赵新汉

（西安交通大学第一附属医院肿瘤科，陕西 西安，710061）

浏览次数：88次 下载次数：401次

摘要：

目的 研究晚期三阴乳腺癌应用吉西他滨与顺铂二线治疗的临床效果。方法 选取我院2014年6月至2016年9月收治的晚期三阴乳腺癌患者80例为研究对象，将其按照数字随机化法分为对照组和试验组，各40例。对照组采用常规治疗方式，试验组在对照组的基础上采用吉西他滨联合顺铂进行二线治疗。比较两组患者的临床治疗效果及不良反应发生情况。结果 试验组患者的治疗总有效率为82.50%，明显高于对照组的52.50%（P<0.05）。试验组患者的肺部、肝部及胸壁、淋巴结转移部位的治疗总有效率均明显高于对照组（P<0.05）。试验组患者的不良反应总发生率明显低于对照组（P<0.05）。结论 晚期三阴乳腺癌应用吉西他滨与顺铂二线治疗的效果显著，并发症发生率低，具有较高临床推广价值。

关键词：晚期三阴乳腺癌；吉西他滨；顺铂；二线治疗

中图分类号：R737.9文献标志码：A文章编号：2096-1413(2017)25-0013-02

Efficacy of gemcitabine and cisplatin in the second-line treatment of advanced stage of triple negative breast cancer
LIU Shu-song, ZHAO Xin-han
(Department of Oncology, the First Affiliated Hospital of Xi``an Jiaotong University, Xi``an 710061, China)

ABSTRACT: Objective To study the effect of gemcitabine and cisplatin in the second-line treatment of advanced stage of triple negative breast cancer. Methods From June 2014 to September 2016, 80 patients with advanced stage of triple negative breast cancer in our hospital were selected as the research objects, and were divided into control group and experimental group according to the digital randomization methods, with 40 patients in each group. The control group was treated with conventional treatment, the experimental group was treated with gemcitabine and cisplatin on the basis of the control group. The clinical treatment efficacy and incidence of adverse reactions in the two groups were compared. Results The total effective rate was 82.50% in the experimental group, which was significantly higher than 52.50% in the control group (P<0.05). The total effective rates of metastatic sites such as lung, liver and chest wall and lymph node in the experimental group were significantly higher than those of the control group (P<0.05). The total incidence of adverse reactions in the experimental group was significantly lower than that of the control group (P<0.05). Conclusion Gemcitabine and cisplatin has remarkable effect and lower adverse reactions rate in the second-line treatment of advanced stage of triple negative breast cancer, which has a high clinical promotion value.
KEYWORDS: advanced stage of triple negative breast cancer; gemcitabine; cisplatin; second-line treatment

参考文献：
[1] 梁振华.吉西他滨联合顺铂治疗三阴性晚期乳腺癌的临床疗效分析[J].世界最新医学信息文摘,2016,16(13):21,43.
[2] 徐家亮,徐春华.晚期三阴乳腺癌应用吉西他滨联合顺铂二线治疗的效果观察[J].当代医学,2016,22(8):149-150.
[3] 李伟,宋霆婷,张海燕,等.吉西他滨联合顺铂治疗三阴性和非三阴性乳腺癌的临床疗效及安全性分析[J].实用癌症杂志,2016,31(5):754-756.
[4] 詹颖,童远和,陈志勇,等.吉西他滨联合顺铂与多西他赛联合顺铂在晚期三阴乳腺癌化疗中的对比研究[J].中国现代医生,2016,54(17):67-69,74.
[5] 杨慧,黄海欣,李桂生.吉西他滨联合卡铂或顺铂治疗晚期三阴乳腺癌的疗效观察[J].现代肿瘤医学,2014,22(5):1076-1078.
[6] 李金燕.吉西他滨联合顺铂治疗蒽环类及紫杉类耐药的转移性三阴乳腺癌临床观察[J].中国临床研究,2014,27(10):1206-1208.
[7] 张萍海,王碧芸,陈雅娟,等.吉西他滨治疗转移性三阴性乳腺癌的疗效和进展[J].中国癌症杂志,2012,22(8):627-631.
[8] 张文霞,张一卓,邹富琴.三阴和非三阴性乳腺癌吉西他滨联合顺铂治疗对照研究[J].中华肿瘤防治杂志,2013,20(22):1751-1754.
[9] 赵增虎,刘俊堂,丁瑞亮,等.吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32 例临床观察[J].解放军医药杂志,2013,25(1):36-38.